Rachel Liberatore is the founder of RenBio. RenBio has raised $49M in total funding. Latest round: Series A. Based in Long Island City, New York.
Rachel Liberatore is the President and Chief Scientific Officer of RenBio. RenBio focuses on developing ultra long-lasting, DNA-based delivery of incretin receptor agonists for the treatment of obesity and other metabolic diseases, utilizing their proprietary MYO Technology™ platform. Liberatore presented on this technology at the Obesity Conference 2026.
Full founder directory · Investor directory · Company funding database · Fundraising library